ストックスクリーナーアプリを入手
6.75
2.17%
-0.15
前日終値:
$6.90
開ける：
$6.8
24時間の取引高:
833.86K
Relative Volume:
0.55
時価総額：
$708.01M
収益：
-
当期純損益:
$-57.39M
株価収益率:
-4.5925
EPS:
-1.4698
ネットキャッシュフロー:
$-45.79M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
+51.69%
6か月 パフォーマンス:
+239.20%
1年 パフォーマンス:
+2,495%
1日の値動き範囲:
$6.614
$6.8778
1週間の範囲:
$6.6013
$7.37
52週間の値動き範囲:
$0.243
$7.51
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs PSNYW, GOODO, SHMD, DWLD, QQQE
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
4.275 | 395.46M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
19.65 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.46 | 303.59M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
44.15 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.69 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
| 2026-01-23 | 再開されました | Leerink Partners | Outperform |
| 2025-12-22 | 開始されました | Jefferies | Buy |
| 2025-11-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - stocktitan.net
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
RLMD PE Ratio & Valuation, Is RLMD Overvalued - intellectia.ai
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - stocktitan.net
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - msn.com
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com
Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget
Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com
RLMD stock surges 42% in a week: Here's what you should know - MSN
how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com Canada
how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN
Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey
Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - GuruFocus
Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus
Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com
Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn
Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart
Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks
Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks
Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan
Relmada Therapeutics price target raised to $19 from $10 at Mizuho - TipRanks
RLMD: Mizuho Analyst Raises Price Target to $19, Maintains Outpe - GuruFocus
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00 - MarketBeat
Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho - StreetInsider
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
Relmada Therapeutics Inc (RLMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
0.47%
2.75%
大文字化:
|
ボリューム (24 時間):